Literature DB >> 30203317

Complement your knowledge with a rare cause of pauci-immune glomerulonephritis.

H Lomzenski1, R Thibodaux2, M Guevara2.   

Abstract

RPGN can be subdivided into three categories on an immunopathologic basis: pauci-immune glomerulonephritis (PIGN), anti-glomerular basement membrane glomerulonephritis (anti-GBM disease), or immune complex-mediated glomerulonephritis (GN). PIGN is the most common cause of RPGN (80% of cases). The most common etiology of PIGN is anti-neutrophil cytoplasmic antibody (ANCA)-associated GN, which accounts for up to 90% of PIGN. PIGN is unique in that few to no immunoglobulin deposits are seen on glomerular immunofluorescence (IF) and electron microscopy (EM), but it is important to remember that dysregulation of the alternative pathway may result in the deposition of complements leading to inflammatory injury even in PIGN. Membranoproliferative glomerulonephritis (MPGN) is a rare, primary glomerular disorder. Both ANCA-associated GN and complement-mediated MPGN will lack immunoglobulin staining on immunofluorescence (IF) and thus present as PIGN on pathologic examination. This may lead to occurrences where these entities mimic one another, therefore necessitating heightened suspicion and close pathologic examination of a renal biopsy with electron microscopy to differentiate the diagnoses. This case highlights a rare case of C3 GN mimicking ANCA-associated GN.

Entities:  

Keywords:  C3 glomerulonephritis; Complement-mediated glomerulonephritis; Membranoproliferative glomerulonephritis; Pauci-immune ANCA-associated glomerulonephritis

Mesh:

Substances:

Year:  2018        PMID: 30203317     DOI: 10.1007/s10067-018-4275-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  12 in total

Review 1.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

Review 2.  The role of complement in C3 glomerulopathy.

Authors:  Peter F Zipfel; Christine Skerka; Qian Chen; Thorsten Wiech; Tim Goodship; Sally Johnson; Veronique Fremeaux-Bacchi; Clara Nester; Santiago Rodríguez de Córdoba; Marina Noris; Matthew Pickering; Richard Smith
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

3.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

4.  Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases.

Authors:  Mark Haas; Joseph A Eustace
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

5.  Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis.

Authors:  Min Chen; Guang-Qun Xing; Feng Yu; Gang Liu; Ming-Hui Zhao
Journal:  Nephrol Dial Transplant       Date:  2008-10-21       Impact factor: 5.992

Review 6.  Dominant C3 glomerulopathy: new roles for an old actor in renal pathology.

Authors:  Nicola Pirozzi; Antonella Stoppacciaro; Paolo Menè
Journal:  J Nephrol       Date:  2017-11-18       Impact factor: 3.902

7.  The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis.

Authors:  Olumide Olatubosun Rowaiye; Mariusz Kusztal; Marian Klinger
Journal:  Clin Kidney J       Date:  2015-04-05

Review 8.  Pauci-Immune Crescentic Glomerulonephritis: An ANCA-Associated Vasculitis.

Authors:  Rafeel Syed; Amina Rehman; Gautam Valecha; Suzanne El-Sayegh
Journal:  Biomed Res Int       Date:  2015-11-25       Impact factor: 3.411

Review 9.  C3 glomerulopathy and current dilemmas.

Authors:  Naoko Ito; Ryuji Ohashi; Michio Nagata
Journal:  Clin Exp Nephrol       Date:  2016-11-23       Impact factor: 2.801

10.  An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Authors:  Yi Yang; Harriet Denton; Owen R Davies; Kate Smith-Jackson; Heather Kerr; Andrew P Herbert; Paul N Barlow; Matthew C Pickering; Kevin J Marchbank
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121

View more
  1 in total

1.  C3 glomerulonephritis associated with ANCA positivity: a case report.

Authors:  Ling Li; Li-Qin Liu; Ying-Ying Yang; Zhang-Xue Hu
Journal:  BMC Nephrol       Date:  2021-04-21       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.